JP2024515968A - 抗ｇａｌ３抗体製剤およびその使用法 - Google Patents

抗ｇａｌ３抗体製剤およびその使用法 Download PDF

Info

Publication number
JP2024515968A
JP2024515968A JP2023565628A JP2023565628A JP2024515968A JP 2024515968 A JP2024515968 A JP 2024515968A JP 2023565628 A JP2023565628 A JP 2023565628A JP 2023565628 A JP2023565628 A JP 2023565628A JP 2024515968 A JP2024515968 A JP 2024515968A
Authority
JP
Japan
Prior art keywords
months
antibody
pharmaceutical formulation
sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565628A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022231978A5 (https=
JP2024515968A5 (https=
Inventor
サン，ドンフ
ヘ，ヤン
チェン，ファン
チャンダリア，アプルヴァ
シチョルス，クセニヤ
Original Assignee
トゥルーバインディング，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トゥルーバインディング，インコーポレイテッド filed Critical トゥルーバインディング，インコーポレイテッド
Publication of JP2024515968A publication Critical patent/JP2024515968A/ja
Publication of JPWO2022231978A5 publication Critical patent/JPWO2022231978A5/ja
Publication of JP2024515968A5 publication Critical patent/JP2024515968A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2023565628A 2021-04-26 2022-04-22 抗ｇａｌ３抗体製剤およびその使用法 Pending JP2024515968A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163179879P 2021-04-26 2021-04-26
US63/179,879 2021-04-26
PCT/US2022/026005 WO2022231978A1 (en) 2021-04-26 2022-04-22 Anti-gal3 antibody formulations and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2024515968A true JP2024515968A (ja) 2024-04-11
JPWO2022231978A5 JPWO2022231978A5 (https=) 2025-04-28
JP2024515968A5 JP2024515968A5 (https=) 2025-04-28

Family

ID=83848624

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565628A Pending JP2024515968A (ja) 2021-04-26 2022-04-22 抗ｇａｌ３抗体製剤およびその使用法

Country Status (5)

Country Link
US (1) US20240158512A1 (https=)
EP (1) EP4329804A4 (https=)
JP (1) JP2024515968A (https=)
CN (1) CN117561080A (https=)
WO (1) WO2022231978A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
WO2025064944A1 (en) * 2023-09-20 2025-03-27 Vor Biopharma Inc. Anti-cd45 antibody-drug conjugate pharmaceutical compositions
CN121263444A (zh) * 2024-03-08 2026-01-02 孙氏医药有限公司 抗半乳糖凝集素3抗体和其在癫痫和相关疾病中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020160156A2 (en) * 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
AU2018263868A1 (en) * 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
WO2021242776A2 (en) * 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020160156A2 (en) * 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KANG, J. ET AL.: "Rapid Formulation Development for Monoclonal Antibodies", BIOPROCESS INTERNATIONAL, [ONLINE], JPN6022017107, 12 April 2016 (2016-04-12), ISSN: 0005829045 *
TAO, C. C. ET AL.: "Galectin-3 promotes Aβ oligomerization and Aβ toxicity in a mouse model of Alzheimer's disease", CELL DEATH AND DIFFERENTIATION, vol. 27, no. 1, JPN6026012604, 2020, pages 192 - 209, ISSN: 0005829046 *
内山 進 ほか: "抗体医薬品の溶液物性", 薬剤学, vol. 第74巻, 第1号, JPN6025003447, 2014, pages 12 - 18, ISSN: 0005829044 *

Also Published As

Publication number Publication date
WO2022231978A1 (en) 2022-11-03
EP4329804A4 (en) 2025-03-19
CN117561080A (zh) 2024-02-13
US20240158512A1 (en) 2024-05-16
EP4329804A1 (en) 2024-03-06

Similar Documents

Publication Publication Date Title
JP2024515968A (ja) 抗ｇａｌ３抗体製剤およびその使用法
US20250243282A1 (en) Methods of treating inflammatory diseases by blocking galectin-3
JP7458399B2 (ja) 抗クローディン抗体及びそれらの使用
US20250145722A1 (en) Anti-gal3 antibodies and methods of use
US20230279120A1 (en) Methods of treating or inhibiting cardiovascular diseases
US20250026838A1 (en) Methods of preventing protein aggregation
US20220411514A1 (en) Anti-gal3 antibodies and methods of use for insulin resistance
US20230094463A1 (en) Antibodies that disrupt the interaction of gal3 and insulin receptor or integrins and methods of use thereof
HK40078860A (en) Anti-gal3 antibodies and methods of use
HK40059021A (en) Anti-claudin antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250418

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260331